Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 18, 2010

Asuragen to Manufacture RNA Control Kits for Affymetrix to Use in Molecular Diagnostics

  • Asuragen is to develop and manufacture RNA Control Kits for Affymetrix for use with its in vitro transcription reagent kits for clinical molecular diagnostic applications. Asuragen says the cGMP RNA Control Kits will be configured for use with the GeneChip® System 3000Dx v.2.

    The kits will reportedly allow Affymetrix to deliver a complete solution to its molecular diagnostic partners. The GeneChip System 3000Dx v.2 is the only diagnostic microarray platform to have been granted FDA 510(k) clearance and a EU CE mark, Asuragen points out.

    As a fully integrated diagnostics company and molecular biology service provider, Asuragen is focused on molecular oncology and genetic diseases. With expertise in the miRNA field, the firm’s current diagnostic portfolio includes Signature® genetic-testing and oncology-testing products as well as controls and standards engineered using its patented Armored RNA® technology.

     

     



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »